Search
Results
showing 1-10 of 2344
Advancing Access to LEN for PrEP
November 2026
Working with Ministries of Health (MoH), civil society and key stakeholders to support community-centered, strategic planning and rollout of LEN for PrEP in three early adopter countries.
Advancing Access to LEN for PrEP
November 2026
AVAC is pleased to share, Advancing Access to LEN for PrEP, highlighting the approaches that led to strong, sustainable, community-centered LEN introductions in Kenya, Malawi and Uganda. It documents the lessons learned and shares resources that can help other countries determine how to effectively prepare for and deliver LEN and future PrEP options.
Advancing Access to LEN for PrEP in Kenya, Malawi and Uganda: Communications Toolkit
November 2026
These communication materials were created during the Advancing Access to LEN for PrEP projects in Kenya, Malawi and Uganda. Partners worked with government and communities to develop tailored materials to raise awareness of LEN for PrEP, situating it among other available prevention options as a way of facilitating informed choice. Across the three countries, 36 demand-generation materials were developed with community input.
Global Health Watch: What a New US Congress Could Mean for Science + Global Health, America First Global Health Strategy, Measles Resurgence
November 2026
The wave of newly elected US lawmakers with backgrounds in science and global health offers new opportunities for advocacy and oversight; a ProPublica exposé reveals nearly $40 million in federal health security awards to a company linked to the US President’s family amid the rollout of the “America First Global Health Strategy”; and the potential loss of US measles elimination status underscores the consequences of eroding trust in science and the spread of disinformation.
Going Faster with LEN Generics
November 2026
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.
Clinical Trial Design Academy: Shaping the Future of HIV R&D
November 2026
AVAC’s Clinical Trial Design Academy (CTDA), established in 2019, is the only program of its kind equipping advocates with the scientific knowledge and skillset to influence research and development (R&D) from priority setting and upstream vaccine, bNAb, ARV and MPT research through ongoing efficacy trials, results dissemination, implementation science and, ultimately, access. Today, the Academy’s 27 members are premier advocates who are directly influencing HIV research. Last month, the Academy gathered in Cape Town, South Africa. Read on to learn more about the Academy and the advocates who are bridging the gap between science and communities.
From Capacity to Advocacy: How the CTDA Is Shaping My Role in HIV Research
November 2026
When Idah Mulalah joined AVAC’s Clinical Trial Design Academy (CTDA) in 2024, she thought it would be like joining any other group where we meet, discuss, learn and move on. In this guest blog post, she reflects on how much the experience has transformed her understanding of clinical trials, and how she sees her role as an HIV prevention research advocate.
Topic:
showing 1-10 of 2344